Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non Operating Income (2020 - 2025)

Historic Other Non Operating Income for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $37000.0.

  • Apellis Pharmaceuticals' Other Non Operating Income fell 4714.29% to $37000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 83924.73%. This contributed to the annual value of -$2.2 million for FY2024, which is 19848.69% down from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Other Non Operating Income stood at $37000.0, which was down 4714.29% from $146000.0 recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Other Non Operating Income registered a high of $219000.0 during Q4 2023, and its lowest value of -$55.2 million during Q4 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' median Other Non Operating Income value was -$246000.0 (recorded in 2022), while the average stood at -$5.3 million.
  • In the last 5 years, Apellis Pharmaceuticals' Other Non Operating Income crashed by 90593.61% in 2024 and then surged by 50833.33% in 2025.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Other Non Operating Income stood at -$55.2 million in 2021, then skyrocketed by 99.55% to -$246000.0 in 2022, then surged by 189.02% to $219000.0 in 2023, then crashed by 905.94% to -$1.8 million in 2024, then soared by 102.1% to $37000.0 in 2025.
  • Its Other Non Operating Income stands at $37000.0 for Q3 2025, versus $146000.0 for Q2 2025 and -$165000.0 for Q1 2025.